Benefit/risk ratio of statins in primary prevention
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Both the US and European guidelines for cardiovascular disease prevention recommend lipid-lowering drugs, particularly a statin, if risk of a cardiovascular event exceeds 10% in 10 years. The benefit of statin therapy for primary prevention in asymptomatic people has little supporting evidence. This is particularly true for elderly people whose risk of cardiovascular events exceeds this threshold because of their age but who have none of the major risk factors for such events other than a low-density lipoprotein level above the desired concentration. Furthermore, the risks of long-term statin therapy appear to be undervalued.